Gilead Sciences, Inc. (GILD) News
Filter GILD News Items
GILD News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest GILD News From Around the Web
Below are the latest news stories about Gilead Sciences Inc that investors may wish to consider to help them evaluate GILD as an investment opportunity.
Gilead Sciences (GILD) and collaboration partner Galapagos NV (GLPG) announce week 52 results from two Phase 3 clinical trials, FINCH 1 and FINCH 3, evaluating JAK1 inhibitor filgotinib in adults with moderately to severely active rheumatoid arthritis ((RA)). The data are being virtually presented at EULAR.80.7% (n=1,417/1,755) of participants in...
Diamond Hill Capital recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Diamond Hill Small Cap Fund posted a return of -36.17% for the quarter, underperforming its benchmark, the Russell 2000 Index which returned -30.61% in the same quarter. You should check out Diamond Hill Capital's top 5 […]
Many people who are closely following developments in the COVID-19 pandemic are familiar with remdesivir. Gilead Sciences' (NASDAQ: GILD) investigational antiviral drug has been seen by many as a promising treatment option for the coronavirus. In February, Bruce Aylward of the World Health Organization said, "There is only one drug right now that we think may have real efficacy and that's remdesivir."
Gilead (GILD) rides high on potential sales from its experimental coronavirus treatment, remdesivir, and collaboration with Arcus.
There are few names more well-known in the biopharmaceutical world than Bristol Myers Squibb (NYSE: BMY) and Gilead Sciences (NASDAQ: GILD). Gilead has gained increasing attention in the news of late. In early May, the U.S. Food and Drug Administration (FDA) authorized the emergency use of the company's antiviral medication remdesivir to treat critically ill COVID-19 patients.
Galapagos rose nearly 3% in early Amsterdam trade as Phase 3 studies of drug it's making with Gilead Sciences showed "sustained efficacy and a consistent safety profile" in treating moderately to severely active rheumatoid arthritis. The companies said they will be presenting the data on filgotinib at the European League Against Rheumatism's European E-Congress of Rheumatology 2020.
Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced Week 52 results from the Phase 3 FINCH 1 and FINCH 3 studies of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately to severely active rheumatoid arthritis (RA). The data demonstrate sustained efficacy and a consistent safety profile with up to 52 weeks of filgotinib treatment across RA patient populations. The new data are among 15 abstracts on filgotinib in RA that will be presented at the European League Against Rheumatism, EULAR, European E-Congress of Rheumatology 2020.
SEOUL --- South Korea's Drug Ministry said Wednesday it was negotiating with US-based Gilead Sciences for emergency imports of remdesivir, a drug candidate that has shown clinical efficacy in treating COVID-19. Remdesivir is Gilead Science's proposed drug candidate for Ebola, which has been circuited to test its effect on the latest coronavirus pandemic. In a pan-global clinical trial encompassing 73 institutes across 10 nations targeting over 1,000 COVID-19 patients, patients who were given remdesivir recovered 31 percent faster than those who were given placebo. The median number of days to recovery had shortened from 15 days to 11 days. The ministry said that it decided t… Keep on reading: S. Korea allows emergency imports of remdesivir
The consensus estimates for Gilead Sciences, Inc. (NASDAQ: GILD ) appear overly conservative, especially given the prospects of remdesivir and products from the company’s recent collaboration with Arcus Biosciences Inc (NYSE: RCUS ), according to Leerink. The Gilead Sciences Analyst Geoffrey Porges upgraded Gilead Sciences from Market Perform to Outperform and raised the price target from $85 to $94. The Gilead Sciences Thesis Remdesivir is likely to be sold for both commercial use and government stockpiles, reaching a revenue peak of $7.7 billion in 2022, Porges said in the Wednesday upgrade note. Stockpile sales could begin by late 2021, the analyst said, adding that … Full story available on Benzinga.com
Shares of Gilead Sciences Inc. undefined gained 1.1% in premarket trading on Wednesday after SVB Leerink upgraded the drugmaker to outperform from market…